Taylor Jensen,
Director, Research and Development,
Sequenom (a LabCorp Company)
Dr. Jensen serves as Director of Research and Development at Sequenom, a wholly owned subsidiary of Laboratory Corporation of America. He joined Sequenom in 2009 and was part of the team that developed and launched the first commercially available noninvasive prenatal test based on circulating cell-free DNA (cfDNA) in the U.S. Since that time, Dr. Jensen has been involved in numerous assay development efforts focused on the detection of genetic and epigenetic changes in cfDNA for use in both the prenatal and oncology fields with the overarching goal of utilizing these aberrations to improve human health. Prior to joining Sequenom, Dr. Jensen received his B.S. degree in biology from Utah State University and completed his PhD in Pharmacology and Toxicology from the University of Arizona.
Low Coverage, Genome-Wide Sequencing of Cell-free DNA Enables the Monitoring of Response to Immunotherapy in Cancer Patients
Thursday, 5 October 2017 at 16:30
Add to Calendar ▼2017-10-05 16:30:002017-10-05 17:30:00Europe/LondonLow Coverage, Genome-Wide Sequencing of Cell-free DNA Enables the Monitoring of Response to Immunotherapy in Cancer PatientsLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Inhibitors of the PD-1/PD-L1/CTLA4 immune checkpoint pathway have revolutionized cancer treatment with a subset of patients showing durable responses; however, challenges remain in the development of biomarkers to predict or monitor response to these therapies. The use of cell-free DNA (cfDNA) isolated from plasma, or liquid biopsy, provides a promising method for monitoring response. In contrast to methods that use ultra-deep (>30,000X) targeted sequencing, we will describe a recently completed a proof-of-concept study using low-coverage (~0.3X), genome-wide sequencing of cfDNA to detect tumor-specific copy number alterations. As part of this study, we have developed a novel metric, the Genome Instability Number (GIN), to monitor response to these drugs throughout treatment. In a series of case studies, we will describe how the GIN can be used to discriminate clinical response from progression, differentiate progression from pseudoprogression and identify hyperprogressive disease. In addition, we have utilized this metric to provide evidence for a delayed pharmacokinetic response for checkpoint inhibitors relative to targeted therapies.
Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-10-05 16:30:002017-10-05 17:30:00Europe/LondonLow Coverage, Genome-Wide Sequencing of Cell-free DNA Enables the Monitoring of Response to Immunotherapy in Cancer PatientsLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
_150x75.jpg)
.gif){kind=logo}
